NEXT Oncology

Summary

NEXT Oncology is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Cancer, Pancreatic Cancer, Lung Cancer, Colorectal Cancer and other specialties. NEXT Oncology is involved with conducting 162 clinical trials across 131 conditions. There are 12 research doctors associated with this hospital, such as Anthony Tolcher, M.D, David Sommerhalder, MD, Sharon T Wilks, MD, FACP, and Raghad Karim, MD.

Top PIs

Clinical Trials running at NEXT Oncology

Solid Tumors

Pancreatic Cancer

Cancer

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Ovarian Cancer

Esophageal Cancer

Non-Small Cell Lung Cancer

HH2853

for Non-Hodgkin's Lymphoma

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

Recruiting

1 award

Phase 1 & 2

TUB-030

for Cancer

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

Recruiting

1 award

Phase 1 & 2

3 criteria

WEF-001

for Cancer

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Recruiting

1 award

Phase 1 & 2

3 criteria